covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Resultados del tratamiento de la acromegalia en un hospital terciario. ¿Es siem...
Información de la revista
Vol. 54. Núm. 3.
Páginas 145-150 (marzo 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 54. Núm. 3.
Páginas 145-150 (marzo 2007)
Originales
Acceso a texto completo
Resultados del tratamiento de la acromegalia en un hospital terciario. ¿Es siempre la cirugía el tratamiento de elección?
Results of treatment of acromegaly at a tertiary care center. Is surgery always the best choice?
Visitas
4345
M. Luisa Isidroa,
Autor para correspondencia
lisidro@canalejo.org

Correspondencia: Dra. M.L. Isidro. Servicio de Endocrinología. Hospital Juan Canalejo. As Xubias, 84. 15006 A Coruña. España.
, José A. Castroa, Manuel A. Penína, Jacinto Armentaa, Fernando Cordidoa,b
a Servicio de Endocrinología. Hospital Juan Canalejo. A Coruña. España
b Departamento de Medicina. Universidad de A Coruña. A Coruña. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Objetivos

El objetivo de este estudio es conocer las características de nuestros pacientes acromegálicos y evaluar los resultados de la aplicación de los protocolos de tratamiento habituales.

Pacientes y métodos

Se incluyó a todos los pacientes registrados con el diagnóstico de acromegalia (n=42). Se recogieron datos demográficos, estudio hormonal, función visual y pruebas de imagen al diagnóstico y durante el seguimiento, y tratamientos recibidos.

Resultados

En el 71,4% de los casos la acromegalia se debía a un macroadenoma hipofisario. El 63,2% del total de los pacientes fue sometido a tratamiento quirúrgico y el 36,8% recibió tratamiento radioterápico; 35 pacientes están recibiendo tratamiento médico, 11 de ellos como terapia primaria. Aplicando los criterios actuales, la cirugía no ha curado la acromegalia a ninguno de nuestros pacientes. Considerando concentraciones de factor de crecimiento similar a la insulina tipo 1 (IGF-1) normales para la edad y el sexo como criterio de control de la enfermedad, el tratamiento quirúrgico ha controlado la enfermedad en el 8,3% de los pacientes operados, mientras que la terapia médica ha controlado la enfermedad en el 71,4% de los pacientes (p<0,05). De los pacientes en tratamiento médico como terapia primaria, en el 45,5% el tumor ha disminuido de tamaño y en el resto no se han producido cambios significativos durante el seguimiento.

Conclusiones

A diferencia de lo que ocurre con el tratamiento médico, con el tratamiento quirúrgico no en todos los centros se consiguen los resultados publicados en la literatura médica. Al menos en algunos hospitales quizá debería optarse por el tratamiento médico primario de la acromegalia, si el paciente no presenta afectación visual.

Palabras clave:
Acromegalia
Tratamiento
Análogos de la somatostatina
Objective

To determine the characteristics of our acromegalic patients and to evaluate the results of applying the usual treatment schedules.

Patients and methods

All acromegalic patients were included (n=42). Demographic and hormonal data, visual function and imaging tests at diagnosis and during follow-up, as well as treatment, were recorded.

Results

Acromegaly was due to a pituitary macroadenoma in 71.4% of the patients. Surgery was performed in 63.2% of all the patients and radiotherapy was used in 36.8%. Medical treatment is being provided in 35 patients and is the primary therapeutic approach in 11 of these. With the currently used criteria, none of the patients has been cured by surgery. Considering age and sex-matched normal concentrations of insulin-like growth factor-1 (IGF-1) as a criteria of disease control, surgery has resulted in disease control in 8.3% of operated patients, while medical treatment has controlled the disease in 71.4% of patients (P<0.05). Of the patients receiving medical treatment as the primary therapeutic approach, tumoral size has decreased in 45.5%, while no significant change in tumoral size has been observed in the remaining patients.

Conclusions

In contrast with medical treatment, when surgery is used, not all centres obtain the results reported in the literature. At least in some hospitals, opting for primary medical treatment might be reasonable in patients without visual disturbances.

Key words:
Acromegaly
Treatment
Somatostatin analogs
El Texto completo está disponible en PDF
Bibliografía
[1.]
S. Melmed, F. Casanueva, F. Cavagnini, P. Chanson, L.A. Frohman, R. Gaillard, et al.
Consensus statement: medical management of acromegaly.
Eur J Endocrinol, 153 (2005), pp. 737-740
[2.]
S. Melmed, F. Casanueva, F. Cavagnini, P. Chanson, L.A. Frohman, A. Grossman, et al.
Guidelines for acromegaly management.
J Clin Endocrinol Metab, 87 (2002), pp. 4054-4058
[3.]
A. Giustina, A. Barkan, F.F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, et al.
Criteria for cure of acromegaly: a consensus statement.
J Clin Endocrinol Metab, 85 (2000), pp. 526-529
[4.]
P.U. Freda, K.D. Post, J.S. Powell, S.L. Wardlaw.
Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
J Clin Endocrinol Metab, 83 (1998), pp. 3808-3816
[5.]
O. Serri, C. Beauregard, J. Hardy.
Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegegaly.
J Clin Endocrinol Metab, 89 (2004), pp. 658-661
[6.]
S. Gullu, H. Keles, T. Delibasi, V. Tonyukuk, N. Kamel, G. Endorgan.
Remission criteria for the follow-up of patients with acromegaly.
Eur J Endocrinol, 150 (2004), pp. 465-471
[7.]
S.M. Shalet.
Biochemical monitoring of disease activity after surgery for acromegaly.
J Clin Endocrinol Metab, 89 (2004), pp. 492-494
[8.]
I. Shimon, S. Melmed.
Management of pituitary tumors.
Ann Intern Med, 129 (1998), pp. 472-483
[9.]
E. Erturk, E. Tuncel, S. Kiyici, C. Ersoy, C. Duran, S. Imamoglu.
Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience.
Pituitary, 8 (2005), pp. 93-97
[10.]
D. Jenkins, I. O’Brien, A. Jonhson, R. Shakespear, M.C. Sheppard, P.M. Stewart.
The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly.
Clin Endocrinol (Oxf), 43 (1995), pp. 517-522
[11.]
S. Yamada, T. Aiba, K. Takada, Y. Ozawa, T. Shimizu, S. Sawano, et al.
Retrospective analysis of long-term surgical results in acromegaly: preoperative and postoperative factors predicting outcome.
Clin Endocrinol (Oxf), 45 (1996), pp. 291-298
[12.]
C.A. Lissett, S.R. Pearcey, I. Laing, L. Tetlow, J.R. Davis, S.M. Shalet.
The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
Clin Endocrinol (Oxf), 49 (1998), pp. 653-657
[13.]
A. Mestrón, S.M. Webb, R. Astorga, P. Benito, M. Catalá, S. Gatzambide, et al.
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA).
Eur J Endocrinol, 151 (2004), pp. 439-446
[14.]
A. Bourdelot, J. Coste, V. Hazebroucq, S. Gaillard, L. Cazabat, X. Bertagna, et al.
Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly.
Eur J Endocrinol, 150 (2004), pp. 763-771
[15.]
P. De, D.A. Rees, N. Davies, R. John, J. Neal, R.G. Mills, et al.
Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission.
J Clin Endocrinol Metab, 88 (2003), pp. 3567-3572
[16.]
A. Colao, R. Attanasio, R. Pivonello, P. Cappabianca, L.M. Cavallo, G. Lasio, et al.
Partial surgical removal of GH-secreting pituitary tumors enhances the response to somatostatin analogues in acromegaly.
J Clin Endocrinol Metab, 91 (2006), pp. 85-92
[17.]
P. Petrossians, L. Borges-Martins, C. Espinoza, A. Daly, D. Betea, H. Valdes-Socin, et al.
Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Eur J Endocrinol, 152 (2005), pp. 61-66
[18.]
J. Wass.
Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues.
Eur J Endocrinol, 152 (2005), pp. 693-694
[19.]
P.U. Freda, L. Katznelson, A.J. Van der Lely, C.M. Reyes, S. Zhao, D. Rabinowitz.
Long acting somatostatin analog therapy of acromegaly.
J Clin Endocrinol Metab, 90 (2005), pp. 4465-4473
[20.]
A. Colao, R. Pivonello, P. Cappabianca, R.S. Auriemma, M.C. De Martino, A. Ciccarelli, et al.
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
J Endocrinol Invest, 26 (2003), pp. 53-56
[21.]
P.J. Trainer.
Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
J Endocrinol Invest., 26 (2003), pp. 44-52
[22.]
D.R. Clemmons, K. Chihara, P.U. Freda, K.K. Ho, A. Klibanski, S. Melmed, et al.
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
J Clin Endocrinol Metab, 88 (2003), pp. 4759-4767
[23.]
R.S. Jallad, N.R. Musolino, N.R. Salgado, M.D. Bronstein.
Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Clin Endocrinol (Oxf), 63 (2005), pp. 168-175
[24.]
J.S. Bevan.
Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly.
J Clin Endocrinol Metab, 90 (2005), pp. 1856-1863
[25.]
S. Melmed, R. Sternberg, D. Cook, A. Klibanski, P. Chanson, V. Bonert, et al.
A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
J Clin Endocrinol Metab, 90 (2005), pp. 4405-4410
[26.]
J.S. Bevan, S.L. Atkin, A.B. Atkinson, P.M. Bouloux, F. Hanna, P.E. Harris, et al.
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
J Clin Endocrinol Metab, 87 (2002), pp. 4554-4563
[27.]
R. Cozzi, R. Attanasio, M. Montini, G. Pagani, G. Lasio, S. Lodrini, et al.
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?.
J Clin Endocrinol Metab, 88 (2003), pp. 3090-3098
[28.]
C. Newman, S. Melmed, A. George, D. Torigian, M. Duhaney, P. Snyder, et al.
Octreotide as a primary therapy for acromegaly.
J Clin Endocrinol Metab, 83 (1998), pp. 3034-3040
[29.]
M.C. Sheppard.
Primary medical therapy for acromegaly.
Clin Endocrinol (Oxf), 58 (2003), pp. 387-399
[30.]
R. Cozzi, M. Montini, R. Attanasio, M. Albizzi, G. Lasio, S. Lodrini, et al.
Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
J Clin Endocrinol Metab, 91 (2006), pp. 1397-1403
[31.]
P.J. Jenkins, P. Bates, M.N. Carson, P.M. Stewart, J.A. Wass.
Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly.
J Clin Endocrinol Metab, 91 (2006), pp. 1239-1245
[32.]
A. Attanasio, P. Epamimonda, E. Motti, E. Giugni, L. Ventrella, R. Cozzi, et al.
Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study.
J Clin Endocrinol Metab, 88 (2003), pp. 3105-3112
[33.]
F. Castinetti, D. Taieb, J.M. Kuhn, P. Chanson, M. Tamura, P. Jaquet, et al.
Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion.
J Clin Endocrinol Metab, 90 (2005), pp. 4483-4488
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos